Home/Pipeline/IONIS-MAPTRx (BIIB080)

IONIS-MAPTRx (BIIB080)

Alzheimer's Disease

Phase 2Active (Partnered: Biogen)

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 2

Status

Active (Partnered: Biogen)

Company

Ionis Pharmaceuticals

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is a commercial-stage biotech leader with a mission to discover and deliver life-changing RNA-targeted medicines. The company has achieved multiple industry firsts, including the first approved antisense drug, and has successfully transitioned from a research-focused entity to a fully integrated organization with its own commercial capabilities. Its strategy centers on independently launching medicines in neurology and cardiology while selectively partnering in other areas, backed by a deep, late-stage pipeline and a sustainable technology platform.

View full company profile

Therapeutic Areas

Neurology Cardiometabolic Rare Genetic Diseases

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
itMSCs	Stemedica Cell Technologies	Clinical Development	Active
Aucuba-001	Aucuba Sciences	Preclinical	Active
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
NTRX-07	NeuroTherapia	Phase 2	Active
3D Neuronal Disease Models	BioTalentum	Research	Active
Not Publicly Disclosed	Cerecin	Phase 1/2	Active